Last 12 months
Inside the activity.
0 purchase rows · 31 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 3 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 21, 2019 Filed Nov 23, 2019 02:15 UTC |
Farrell Michael J.Chief Executive Officer
|
GrantResMed Common Stock Options · Derivative | 59,894 | $0.00 Strike: $146.34 | $0.00 |
DisclosureSEC source: 0001127602-19-033626 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,894 Underlying: ResMed Common Stock · 59,894 shares Expires 2026-11-21 F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2020, 2021 and 2022. Read SEC document |
| November 21, 2019 Filed Nov 23, 2019 02:15 UTC |
Farrell Michael J.Chief Executive Officer
|
Tax withholdingResMed Common Stock | 65,802 | $146.34 | $9,629,464.68 |
DisclosureSEC source: 0001127602-19-033626 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,700 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. Read SEC document |
| November 21, 2019 Filed Nov 23, 2019 02:15 UTC |
Farrell Michael J.Chief Executive Officer
|
GrantResMed Common Stock | 117,971 | $146.34 | $17,263,876.14 |
DisclosureSEC source: 0001127602-19-033626 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,502 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2016. The shares were earned on November 21, 2019, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 21:15 UTC |
Sandercock BrettChief Financial Officer
|
GrantResMed Common Stock | 34,408 | $146.34 | $5,035,266.72 |
DisclosureSEC source: 0001127602-19-033573 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,211 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2016. The shares were earned on November 21, 2019, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 21, 2019 Filed Nov 23, 2019 01:09 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
GrantResMed Common Stock Options · Derivative | 70,006 | $0.00 Strike: $146.34 | $0.00 |
DisclosureSEC source: 0001127602-19-033622 · form4.xml · derivative · entry 4 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,006 Underlying: ResMed Common Stock · 70,006 shares Expires 2026-11-21 F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2020, 2021 and 2022. Read SEC document |
| November 21, 2019 Filed Nov 23, 2019 01:09 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Tax withholdingResMed Common Stock | 46,586 | $146.34 | $6,817,395.24 |
DisclosureSEC source: 0001127602-19-033622 · form4.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,671 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. Read SEC document |
| November 21, 2019 Filed Nov 23, 2019 01:09 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
GrantResMed Common Stock | 78,648 | $146.34 | $11,509,348.32 |
DisclosureSEC source: 0001127602-19-033622 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,257 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2016. The shares were earned on November 21, 2019, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 21:04 UTC |
McHale RichardPresident, RC Business
|
Tax withholdingResMed Common Stock | 8,775 | $146.34 | $1,284,133.50 |
DisclosureSEC source: 0001127602-19-033565 · form4.xml · nonDerivative · entry 2 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,670 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 21:04 UTC |
McHale RichardPresident, RC Business
|
GrantResMed Common Stock | 15,731 | $146.34 | $2,302,074.54 |
DisclosureSEC source: 0001127602-19-033565 · form4.xml · nonDerivative · entry 1 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,445 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2016. The shares were earned on November 21, 2019, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 21:02 UTC |
Hollingshead JamesPresident, Sleep Business
|
Tax withholdingResMed Common Stock | 18,633 | $146.34 | $2,726,753.22 |
DisclosureSEC source: 0001127602-19-033557 · form4.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,174 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 21:02 UTC |
Hollingshead JamesPresident, Sleep Business
|
GrantResMed Common Stock | 31,458 | $146.34 | $4,603,563.72 |
DisclosureSEC source: 0001127602-19-033557 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,807 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2016. The shares were earned on November 21, 2019, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 23:00 UTC |
Drexler KarenDirector
|
GrantResMed Common Stock Options · Derivative | 3,889 | $0.00 Strike: $146.34 | $0.00 |
DisclosureSEC source: 0001127602-19-033703 · form4.xml · derivative · entry 2 Drexler Karen · CIK 0001504699 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,889 Underlying: ResMed Common Stock · 3,889 shares Expires 2026-11-21 F2 · derivative.exercise_date: Options vest in full (i) on the first Nov. 11 following the grant date or (ii) the first annual shareholders meeting following grant date. Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 23:00 UTC |
Drexler KarenDirector
|
GrantResMed Common Stock | 863 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-033703 · form4.xml · nonDerivative · entry 1 Drexler Karen · CIK 0001504699 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,387 F1 · kind: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2020, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 21:47 UTC |
TAYLOR RONALD RDirector
|
GrantResMed Common Stock | 1,727 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-033684 · form4.xml · nonDerivative · entry 1 TAYLOR RONALD R · CIK 0001161920 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,582 F1 · kind: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2020, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 20:26 UTC |
FARRELL PETER CDirector
|
GrantResMed Common Stock | 1,727 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-033667 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,028 F1 · kind: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2020, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 20:46 UTC |
SULPIZIO RICHARDDirector
|
GrantResMed Common Stock | 1,727 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-033669 · form4.xml · nonDerivative · entry 1 SULPIZIO RICHARD · CIK 0001191329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,680 F1 · kind: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2020, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 20:24 UTC |
Gill HarjitDirector
|
GrantResMed Common Stock | 1,727 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-033666 · form4.xml · nonDerivative · entry 1 Gill Harjit · CIK 0001759311 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,260 F1 · kind: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2020, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 19:06 UTC |
De Witte JanDirector
|
GrantReMed Common Stock | 1,727 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-033656 · form4.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,133 F1 · kind: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2020, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 18:30 UTC |
Burt CarolDirector
|
GrantResMed Common Stock | 1,727 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-033652 · form4.xml · nonDerivative · entry 1 Burt Carol · CIK 0001493926 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,205 F1 · kind: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2020, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 18:29 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
GrantResMed Common Stock Options · Derivative | 13,223 | $0.00 Strike: $146.34 | $0.00 |
DisclosureSEC source: 0001127602-19-033651 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,223 Underlying: ResMed Common Stock · 13,223 shares Expires 2026-11-21 F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2020, 2021 and 2022. Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 18:29 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Tax withholdingResMed Common Stock | 17,548 | $146.34 | $2,567,974.32 |
DisclosureSEC source: 0001127602-19-033651 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,564 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 18:29 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
GrantResMed Common Stock | 31,458 | $146.34 | $4,603,563.72 |
DisclosureSEC source: 0001127602-19-033651 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,112 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2016. The shares were earned on November 21, 2019, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 18, 2019 Filed Nov 20, 2019 21:08 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
GiftResMed Common Stock | 680 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-033356 · form4.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 153,346 F1 · kind: Gift of shares to The Douglas Family Fund, a donor advised charitable fund. Mr. Douglas has no beneficial interest, control or dispositive power over the gifted shares. Read SEC document |
| November 18, 2019 Filed Nov 20, 2019 21:08 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 1,360 | $146.70 | $199,512.00 |
DisclosureSEC source: 0001127602-19-033356 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 154,026 Read SEC document |
| November 15, 2019 Filed Nov 18, 2019 23:50 UTC |
Hollingshead JamesPresident, Sleep Business
|
Exercise / conversionResMed Common Stock Options · Derivative | 20,038 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-19-033096 · form4.xml · derivative · entry 5 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800 Underlying: ResMed Commmon Stock · 20,038 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| November 15, 2019 Filed Nov 18, 2019 23:50 UTC |
Hollingshead JamesPresident, Sleep Business
|
Exercise / conversionResMed Common Stock Options · Derivative | 1,717 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-19-033096 · form4.xml · derivative · entry 4 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,838 Underlying: ResMed Commmon Stock · 1,717 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| November 15, 2019 Filed Nov 18, 2019 23:50 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 20,038 | $146.35 | $2,932,561.30 |
DisclosureSEC source: 0001127602-19-033096 · form4.xml · nonDerivative · entry 3 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,349 F1 · price: This transaction was executed in multiple trades at prices ranging from $146.07 to 146.80. The price reported above reflects the weighted average sale price. Read SEC document |
| November 15, 2019 Filed Nov 18, 2019 23:50 UTC |
Hollingshead JamesPresident, Sleep Business
|
Exercise / conversionResMed Common Stock | 20,038 | $58.24 | $1,167,013.12 |
DisclosureSEC source: 0001127602-19-033096 · form4.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,387 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2019 Filed Nov 18, 2019 23:50 UTC |
Hollingshead JamesPresident, Sleep Business
|
Exercise / conversionResMed Common Stock | 1,717 | $58.24 | $99,998.08 |
DisclosureSEC source: 0001127602-19-033096 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,349 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 01:24 UTC |
Sodhi RajwantPresident, SaaS Business
|
Tax withholdingResMed Common Stock | 1,696 | $143.88 | $244,020.48 |
DisclosureSEC source: 0001127602-19-032678 · form4.xml · nonDerivative · entry 3 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,787 F4 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 01:24 UTC |
Sodhi RajwantPresident, SaaS Business
|
Tax withholdingResMed Common Stock | 1,185 | $143.88 | $170,497.80 |
DisclosureSEC source: 0001127602-19-032678 · form4.xml · nonDerivative · entry 2 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,483 F3 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/14/2018. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 01:24 UTC |
Sodhi RajwantPresident, SaaS Business
|
Tax withholdingResMed Common Stock | 982 | $143.88 | $141,290.16 |
DisclosureSEC source: 0001127602-19-032678 · form4.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,668 F1 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2017. F2 · balance_after: Includes 98.263 shares of ResMed stock purchased on October 31, 2019, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 01:08 UTC |
Hollingshead JamesPresident, Sleep Business
|
Tax withholdingResMed Common Stock | 2,547 | $143.88 | $366,462.36 |
DisclosureSEC source: 0001127602-19-032673 · form4.xml · nonDerivative · entry 3 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,632 F4 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 01:08 UTC |
Hollingshead JamesPresident, Sleep Business
|
Tax withholdingResMed Common Stock | 1,804 | $143.88 | $259,559.52 |
DisclosureSEC source: 0001127602-19-032673 · form4.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,179 F3 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/14/2018. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 01:08 UTC |
Hollingshead JamesPresident, Sleep Business
|
Tax withholdingResMed Common Stock | 2,134 | $143.88 | $307,039.92 |
DisclosureSEC source: 0001127602-19-032673 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,983 F1 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2017. F2 · balance_after: Includes 70.936 shares of ResMed stock purchased on October 31, 2019, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 01:41 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 1,731 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-19-032680 · form4.xml · derivative · entry 5 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,513 Underlying: ResMed Commmon Stock · 1,731 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 01:41 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Tax withholdingResMed Common Stock | 1,199 | $143.88 | $172,512.12 |
DisclosureSEC source: 0001127602-19-032680 · form4.xml · nonDerivative · entry 4 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,654 F4 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 01:41 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Tax withholdingResMed Common Stock | 727 | $143.88 | $104,600.76 |
DisclosureSEC source: 0001127602-19-032680 · form4.xml · nonDerivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,853 F3 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/14/2018. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 01:41 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Tax withholdingResMed Common Stock | 860 | $143.88 | $123,736.80 |
DisclosureSEC source: 0001127602-19-032680 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,580 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2017. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 01:41 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 1,731 | $57.76 | $99,982.56 |
DisclosureSEC source: 0001127602-19-032680 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,440 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 117.569 shares of ResMed stock purchased on October 31, 2019, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 01:19 UTC |
McHale RichardPresident, RC Business
|
Tax withholdingResMed Common Stock | 1,199 | $143.88 | $172,512.12 |
DisclosureSEC source: 0001127602-19-032675 · form4.xml · nonDerivative · entry 3 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,714 F4 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 01:19 UTC |
McHale RichardPresident, RC Business
|
Tax withholdingResMed Common Stock | 1,189 | $143.88 | $171,073.32 |
DisclosureSEC source: 0001127602-19-032675 · form4.xml · nonDerivative · entry 2 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,913 F3 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/14/2018. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 01:19 UTC |
McHale RichardPresident, RC Business
|
Tax withholdingResMed Common Stock | 1,206 | $143.88 | $173,519.28 |
DisclosureSEC source: 0001127602-19-032675 · form4.xml · nonDerivative · entry 1 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,102 F1 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2017. F2 · balance_after: Includes 117.14 shares of ResMed stock purchased on October 31, 2019, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 00:47 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 6,651 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001127602-19-032669 · form4.xml · derivative · entry 9 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,949 Underlying: ResMed Commmon Stock · 6,651 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F8 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 00:47 UTC |
Farrell Michael J.Chief Executive Officer
|
Tax withholdingResMed Common Stock | 4,495 | $143.88 | $646,740.60 |
DisclosureSEC source: 0001127602-19-032669 · form4.xml · nonDerivative · entry 7 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,531 F7 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 00:47 UTC |
Farrell Michael J.Chief Executive Officer
|
Tax withholdingResMed Common Stock | 2,973 | $143.88 | $427,755.24 |
DisclosureSEC source: 0001127602-19-032669 · form4.xml · nonDerivative · entry 6 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,026 F6 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/14/2018. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 00:47 UTC |
Farrell Michael J.Chief Executive Officer
|
Tax withholdingResMed Common Stock | 3,417 | $143.88 | $491,637.96 |
DisclosureSEC source: 0001127602-19-032669 · form4.xml · nonDerivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,999 F5 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2017. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 00:47 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 8 | $145.17 | $1,161.36 |
DisclosureSEC source: 0001127602-19-032669 · form4.xml · nonDerivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,416 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 00:47 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 3,070 | $144.47 | $443,532.11 |
DisclosureSEC source: 0001127602-19-032669 · form4.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,424 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $144.13 to $145.02. The price reported above reflects the weighted average sale price. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 00:47 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 3,573 | $143.48 | $512,643.32 |
DisclosureSEC source: 0001127602-19-032669 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,494 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $143.12 to 144.12. The price reported above reflects the weighted average sale price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.